Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and chronic photoaging, age, male sex, immunosuppression, smoking and genetic factors. A collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation of Research and Treatment of Cancer (EORTC) was formed to update recommendations on cSCC classification, diagnosis, risk stratification, staging and prevention, based on current literature, staging systems and expert consensus. Common cSCCs are typically indolent tumors, and most have a good prognosis with 5-year cure rates of greater than 90%, and a low rate of metastases (<4%). Further risk stratification into low-risk or high-risk common primary cSCC is recommended based on proposed high-risk factors. Advanced cSCC is classified as locally advanced (lacSCC), and metastatic (mcSCC) including locoregional metastatic or distant metastatic cSCC. Current systems used for staging include the American Joint Committee on Cancer (AJCC) 8th edition, the Union for International Cancer Control (UICC) 8th edition, and Brigham and Women's Hospital (BWH) system. Physical examination for all cSCCs should include total body skin examination and clinical palpation of lymph nodes, especially of the draining basins. Radiologic imaging such as ultrasound of the regional lymph nodes, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT) scans are recommended for staging of high-risk cSCC. Sentinel lymph node biopsy is currently not recommended. Nicotinamide, oral retinoids, and topical 5-FU have been used for the chemoprevention of subsequent cSCCs in high-risk patients but are not routinely recommended. Education about sun protection measures including reducing sun exposure, use of protective clothing, regular use of sunscreens and avoidance of artificial tanning, is recommended.

中文翻译：

---

欧洲关于皮肤浸润性鳞状细胞癌的跨学科指南：第1部分。流行病学，诊断和预防。

浸润性皮肤鳞状细胞癌（cSCC）是白人人群中最常见的癌症之一，占所有皮肤恶性肿瘤的20％。与cSCC病因有关的因素包括紫外线辐射和慢性光老化，年龄，男性，免疫抑制，吸烟和遗传因素。来自欧洲皮肤病学论坛（EDF），欧洲皮肤肿瘤学会（EADO）和欧洲癌症研究与治疗组织（EORTC）的多学科专家组成了一个合作组织，以更新有关cSCC分类，诊断，风险分层的建议，分期和预防，基于当前文献，分期系统和专家共识。常见的cSCC通常是惰性肿瘤，大多数预后良好，五年治愈率超过90％，转移率低（<4％）。根据建议的高风险因素，建议将风险进一步分为低风险或高风险普通原发性cSCC。晚期cSCC分为局部晚期（lacSCC）和转移性（mcSCC），包括局部转移或远处转移性cSCC。当前用于分期的系统包括美国癌症联合委员会（AJCC）第8版，国际癌症控制联盟（UICC）第8版以及布里格姆妇女医院（BWH）系统。所有cSCC的体格检查应包括全身皮肤检查和淋巴结（尤其是流域盆）的临床触诊。放射成像，例如局部淋巴结的超声检查，磁共振成像（MRI），计算机断层扫描（CT），对于高危cSCC的分期，建议使用正电子发射断层扫描计算机断层扫描（PET-CT）扫描。目前不建议进行前哨淋巴结活检。烟酰胺，口服类维生素A和局部5-FU已用于高风险患者后续cSCC的化学预防，但常规不建议使用。建议进行有关防晒措施的教育，包括减少日晒，使用防护服，定期使用防晒霜和避免人工晒黑。